Greenfield vs Retrofit: Compliance Essentials for Life Science Facilities

Key Takeaways: 

• Compliance complexity is increasing. European life sciences projects must satisfy GMP/GxP requirements alongside newer sustainability directives, making multidisciplinary expertise essential on every build.
• Greenfield and retrofit projects carry distinct but equally demanding risks. Greenfield builds require compliance to be embedded from the very first design decisions. Retrofit projects add the burden of qualifying legacy systems that were not designed to current GMP standards.
• Regulatory engagement must begin at the design stage, not the inspection stage. Quality cannot be retrofitted into a facility plan; GMP principles require it to be built in from FEED onwards.
• BIM and digital twins have become standard risk-management tools. On both greenfield and retrofit projects, modelling any conflicts and simulating commissioning scenarios before construction begins significantly reduces problems.
• Energy performance and GMP compliance must be solved together. Meeting EPBD targets without compromising GMP compliance requires mechanical, electrical and validation disciplines to work in alignment from the outset.

Europe’s life sciences sector is building at a pace that would have seemed ambitious a decade ago. New biologics plants are under construction, gene therapy facilities are expanding and established pharmaceutical campuses are undergoing significant reconfiguration. 

But behind every one of these projects there is a compliance issue that is growing in both scope and complexity – and a talent market struggling to keep up.

A Shifting Regulatory Climate

The regulatory framework governing European life sciences facilities has never been more layered. At its core, EudraLex Volume 4 sets out the Good Manufacturing Practice (GMP) guidelines that govern medicinal product manufacturing across EU member states. This is overseen by the European Medicines Agency (EMA), which co-ordinates inspections and GMP/GxP compliance activities at EU level. 

These standards apply whether a company is commissioning a brand-new facility or upgrading an existing one – there is no simplified pathway for retrofit projects.

Layered on top of GMP are two sustainability-driven directives that are changing how facilities are designed and operated: 

• The Energy Performance of Buildings Directive (EPBD) sets out measures to increase energy efficiency across European buildings, creating direct obligations for facility owners and developers. 
• The Corporate Sustainability Reporting Directive (CSRD) requires large companies to report how their operations affect people and the environment – this has real implications for how CapEx projects are scoped, justified and executed.

The cumulative effect is a compliance environment that requires specialists who understand not just GMP/GxP, but also building regulations, energy standards and sustainability reporting. This is driving a sharp increase in demand for multidisciplinary project teams and a corresponding shortage of the right talent.

Two Routes, Different Risks: Greenfield and Retrofit Compared

Greenfield – Starting from scratch 

A greenfield project offers the simplest possible starting point: a clean site, a blank design brief and the freedom to embed compliance from the ground up. In pharma and biotech, this typically means purpose-built cleanroom classifications, specialist HVAC and purified water systems, and a qualification framework that can be planned in full before a single piece of equipment is ordered. 

That freedom, however, comes with its own pressures. Greenfield facilities require commissioning, qualification and validation (CQV) activities to be integrated from the earliest design stages, rather than treated as a final-phase sign-off. This is important because the cost of delays is substantial: a production delay of just one day can cost a pharma company $1 million or more in lost revenue – and CQV activities bolted on at the end of a project are a primary driver of those delays. So, GMP recruitment for CQV specialists must begin well before construction milestones are reached.

Greenfield timelines are also particularly vulnerable to creeping complexity in terms of regulatory documentation. When a facility is designed to house multiple product types, which is increasingly common in contract manufacturing, the validation master plan must account for each process stream, each cleaning regime and each set of equipment. Mistakes made at the design freeze stage are expensive to correct once construction has begun.

Retrofit – When the walls are already in place

Retrofit (also referred to as brownfield development) involves adapting an existing building or facility to meet current GMP/GxP standards. The appeal is clear: existing structures, existing utilities and sometimes an existing workforce. 

However, the challenge is that none of those assets were necessarily designed with today’s regulatory expectations in mind. Also, fitting out a life sciences facility costs three to four times more per floor than a standard office conversion, so the business case for retrofit must be proven before commitment. 

Older buildings, particularly those from the late 1990s and early 2000s, can offer structural advantages, including stronger load-bearing floors and high-capacity power infrastructure. But the same buildings frequently present problems with ceiling heights, air change rates and segregation requirements that are difficult to resolve without significant structural intervention.

Documenting what already exists is often the first and most underestimated challenge on a retrofit project. Change control documentation must capture not just what is being installed but also how it interacts with legacy systems, many of which may not have been formally qualified under current standards. 

Shared Compliance Drivers

1. Early regulatory engagement is a must

Whether the project is greenfield or retrofit, the one consistent finding across major European CapEx builds is that regulatory engagement must begin at the design stage, not the inspection stage. The GMP principles set out in EudraLex Volume 4 are clear that quality must be built into a facility’s design, rather than verified retrospectively. 

This means that CQV specialists need to be part of the design team from FEED (Front End Engineering Design) onwards, not just brought in during commissioning.

2. Integrated CQV

On both project types, CQV is frequently treated as a schedule constraint rather than a project enabler. When validation specialists are brought in late, they encounter systems already installed without GMP design consideration, documentation gaps in construction verification and critical operational inputs that have not yet been defined. The result is a compressed validation timeline that increases compliance risk precisely when regulatory scrutiny is at its highest. 

Structuring CQV resource planning as a parallel workstream is the most effective way to protect both the schedule and compliance.

3. BIM and digital twins: de-risking before the first brick

Building Information Modelling (BIM) and digital twin technology have moved from innovation to expectation on major European life sciences projects. They allow design teams to identify spatial conflicts between cleanroom classifications and process flows before construction begins, for example, and to simulate commissioning scenarios that would otherwise only be tested on live systems. 

For retrofit projects in particular, digital twins allow teams to understand how new installations interact with legacy building fabric, reducing the risk of costly surprises during qualification. 

4. GMP quality alongside sustainability goals

The combination of GMP compliance and energy performance is one of the most difficult aspects of European life sciences construction. Cleanroom environments require precise temperature, humidity and particulate control, all of which are energy-intensive. 

Meeting the EPBD’s energy efficiency requirements without compromising GMP classification can be an engineering challenge, and one that requires mechanical, electrical and validation disciplines to work together. Similarly, CSRD reporting obligations mean that the energy profile of a new or retrofitted facility is now a boardroom consideration, not just a facilities management detail.

Supporting GMP/GxP-Compliant CapEx in Europe

Life science recruitment in Europe requires finding professionals who understand the intersection of engineering, life sciences and regulatory obligations – this is what defines a successful CapEx build. 

At NES Fircroft, we place specialist engineering and life sciences professionals who are experienced in GMP/GxP-compliant CapEx projects – people who understand not just their discipline but also the compliance context in which they are operating. Whether the requirement is for CQV engineers, QA leads, project managers, mechanical designers or cleanroom validation specialists, we source for both greenfield and retrofit projects across the full CapEx lifecycle.

With over 15 regional offices and 20+ years of experience in life science recruitment in Europe, our consultants have direct knowledge of local talent markets, regulatory environments and employment frameworks in countries such as the UK, Ireland, Germany, Switzerland, France, Belgium and the Netherlands. 

From initial sourcing and onboarding through to compliance, payroll, Employer of Record (EOR) services, visa/work permit support and executive search, we provide scalable contract and permanent teams designed to match both project needs and budget parameters. 

If your CapEx project demands the right people, in the right place, with the right compliance credentials, please get in touch.

FAQs

What’s the difference between greenfield and retrofit projects in the life sciences industry?

A greenfield project involves constructing a new life sciences facility on a previously undeveloped site, allowing compliance to be designed in from the outset. A retrofit (or brownfield) project involves repurposing or upgrading an existing building to meet current GMP/GxP and regulatory standards.

What is a greenfield project in pharma and why does it require strict GMP compliance?

A greenfield pharma project is a purpose-built facility, offering full design freedom but carrying significant compliance obligations. GMP compliance is compulsory because regulatory bodies require that manufacturing facilities for medicinal products meet defined standards for premises, equipment and processes, regardless of whether the facility is new or existing.

What are the main compliance challenges when upgrading (retrofitting) life sciences facilities in Europe?

The primary challenges include: documenting and qualifying legacy systems that were not designed to current GMP standards, meeting EPBD energy performance requirements without compromising GMP compliance, and managing complex interactions between new installations and existing building fabric.

What services do CapEx recruitment firms offer for life science expansion projects in Europe?

A specialist in CapEx recruitment in Europe, like NES Fircroft, typically offers end-to-end workforce solutions. These include: specialist sourcing for GMP and technical roles, contract and permanent team deployment, compliance, payroll management, Employer of Record (EOR) services, visa/work permit support, and executive search for senior leadership.

How can I find specialist CQV and GMP talent for greenfield and retrofit projects in Europe?

Working with a specialist life sciences recruiter who has in-market expertise across key European geographies is the most reliable route to qualified CQV and GMP talent. Our life sciences recruitment team has 20+ years of experience placing technical professionals across European CapEx projects – please get in touch to discuss your requirements.